ArticleFrontiers in oncology2025
Association between examined lymph node count and survival in resectable cervical cancer: a retrospective analysis using SEER data.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RNF112 mediates immunosuppression to inhibit the proliferation of cervical cancer by Foxm1.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal examined lymph node (ELN) in resectable nonmetastatic cervical cancer patients remains controversial. Methods: A total of 7435 N0 patients and 1385 N1 patients were enrolled from the Surveillance, Epidemiology, and End Results database. The relationship between ELN and cancer-specific surcical (CSS) was evaluated by restrictive cubic spline (RCS) method. Survival analysis was performed by using Kaplan-Meier method. Results: The median ELN count decreased over years both in N0 and N1 patients. The RCS illustrated nonlinear relationships between ELN counts and prognosis for N0 patients (nonlinearity, p= 0.026; optimal ELN: 13) and N1 patients (nonlinearity, p= 0.024; optimal ELN: 14). Patients were divided into ELN adequate and limited groups according to the optimal cutoff of ELN. The 5-yr and 10-yr survival rates were 94.4% and 92.5% for N0 adequate patients, and 93.9% and 90.0% for N0 limited patients. The 5-yr and 10-yr survival rates were 73.8% and 70.3% for N1 adequate patients, and 68.6% and 63.5% for N1 limited patients. For N0 patients, no survival benefit was found in additional adjuvant treatment. For N1 adequate patients, those with adjuvant radiotherapy obtained greatest survival benefit. For N1 limited patients, those with adjuvant radiotherapy or radiotherapy plus chemotherapy obtained better survival. Conclusions: Nonmetastatic cervical cancer patients with clinical N0 and N1 stages who had at least 13 and 14 ELN counts, respectively, showed better long-term survival. Further prospective studies are needed to validate the association between ELN count and long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.